Clinical trial
INCB88888-040 Multicenter Prospective Real-world Observational Cohort Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
NCT06299553 is registered in ClinicalTrials.gov with Incyte Biosciences Italy S.r.l as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- INCB88888-040 Multicenter Prospective Real-world Observational Cohort Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
- Lead sponsor
- Incyte Biosciences Italy S.r.l
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 4, 2023
- Completion date
- June 30, 2027
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dlbcl - diffuse large b cell lymphoma